{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-056454","form_type":"8-K","ticker":"RMTI","cik":"0001041024","company_name":"ROCKWELL MEDICAL, INC.","filed_at":"2026-08-13T10:14:04+00:00","discovered_at":"2026-08-13T10:15:00.972726+00:00","generated_at":"2026-08-13T10:15:06.578439+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Rockwell Medical Q2 net sales up 11% to $17.8M; net loss narrows to $1.2M","bullets":["Net sales $17.8M, +11% YoY; gross profit $3.2M, +30%; gross margin 18% vs 16%.","Net loss $1.2M vs $1.5M loss; adjusted EBITDA -$0.2M; cash $24.8M at June 30.","Reiterates 2026 guidance: net sales $70-75M, gross margin 18-22%, adj EBITDA $1-2M.","1-for-10 reverse stock split effective July 1, 2026; regained Nasdaq compliance.","New/expanded agreements with Heritage Dialysis and aQua Dialysis during Q2."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-056454","json":"https://secwatch.observer/filing/0001628280-26-056454.json","markdown":"https://secwatch.observer/filing/0001628280-26-056454.md","text":"https://secwatch.observer/filing/0001628280-26-056454.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1041024/000162828026056454/0001628280-26-056454-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1041024/000162828026056454/rmti-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T10:15:06.578439+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}